Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom.
| Revenue (Most Recent Fiscal Year) | $6.85M |
| Net Income (Most Recent Fiscal Year) | $-235.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.45 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1510.27% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -40.39% |
| Return on Assets (Trailing 12 Months) | -29.87% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.11 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.32 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.58 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.38 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.49 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 133.91M |
| Free Float | 124.42M |
| Market Capitalization | $2.23B |
| Average Volume (Last 20 Days) | 1.09M |
| Beta (Past 60 Months) | 1.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.09% |
| Percentage Held By Institutions (Latest 13F Reports) | 82.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |